KALV
NASDAQ HealthcareKalVista Pharmaceuticals, Inc. - Common Stock
Biotechnology
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
๐ Market Data
| Price | $26.65 |
|---|---|
| Volume | 4,863,899 |
| Market Cap | 1.42B |
| Beta | -0.400 |
| RSI (14-Day) | 74.4 Overbought |
| 200-Day MA | $15.07 |
| 50-Day MA | $18.59 |
| 52-Week High | $26.76 |
| 52-Week Low | $9.83 |
| Forward P/E | 21.52 |
| Price / Book | -502.83 |
๐ฏ Investment Strategy Scores
KALV scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (89/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ช Falling Knife (2/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find KALV in your text
Paste any article, transcript, or post โ the tool will extract KALV and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.